Decoding the shared genetic liability of lower respiratory tract infections via genomic structural equation modeling.

Publication date: Jul 07, 2026

Lower respiratory tract infections (LRTI), including pneumonia, tuberculosis, and COVID-19, share overlapping clinical features and risk factors, yet their common genetic architecture remains poorly understood. We applied genomic structural equation modeling (Genomic SEM) to dissect the shared genetic susceptibility among seven LRTI-related phenotypes using large-scale GWAS summary statistics. Multivariate GWAS (mvGWAS) was performed to identify variants associated with the latent LRTI factor. Post-GWAS analyses included Bayesian fine-mapping, transcriptome-wide association studies, MAGMA analysis, pathway enrichment, and cell-type specific heritability partitioning. A single latent factor model demonstrated excellent fit, confirming substantial genetic overlap across LRTI phenotypes. The mvGWAS identified 5,469 genome-wide significant variants, including 3,705 associations uniquely identified at the latent-factor level. Fine-mapping prioritized high-confidence causal variants at CAMK2D, NFKB1, CNTN5 and PARK2 loci, implicating calcium signaling, NF-_705B-mediated inflammation, neuroimmune regulation, and mitochondrial quality control. TWAS highlighted TLK2, NUDT6, and PKN2 as key transcriptional regulators involved in chromatin homeostasis and inflammasome modulation. MAGMA identified RPL18A, HLA-DRB1, HLA-DQB1, and PTPN6, underscoring roles of ribosomal function, antigen presentation, and immune cell signaling. Pathway analysis revealed enrichment in coagulation cascades, while cell type analysis suggested involvement of hematopoietic progenitors and myeloid lineages. This study provides the first comprehensive genetic framework for shared LRTI susceptibility, revealing convergent biological pathways spanning inflammation, mitochondrial homeostasis, antigen presentation, and coagulation. These findings offer candidate targets for host-directed therapeutic strategies.

Open Access PDF

Concepts Keywords
Fine-mapping
Genomic SEM
Post-GWAS
Shared genetic architecture
“””
// Werkzeug Debugger
EVALEX = false,
EVALEX_TRUSTED = false,
in __call__
line 1536,
NotImplementedError

Semantics

Type Source Name
disease MESH pneumonia
disease MESH tuberculosis
pathway KEGG Tuberculosis
disease MESH COVID-19
disease MESH genetic susceptibility
disease MESH included
disease MESH PARK2
disease MESH inflammation
drug DRUGBANK Troleandomycin
pathway REACTOME Reproduction
disease MESH Infectious Diseases
drug DRUGBANK Coenzyme M
disease MESH pulmonary tuberculosis
disease MESH lung abscess
disease MESH death
disease MESH Community acquired pneumonia
disease MESH diabetes mellitus
disease MESH respiratory infections
disease MESH infection
disease MESH influenza
disease MESH HIV coinfection
disease MESH respiratory diseases
disease MESH bacterial pneumonia
disease MESH AIC
disease MESH viral pneumonia
disease MESH ncRNA
disease MESH body weight
disease MESH heart failure
drug DRUGBANK Serine
drug DRUGBANK L-Threonine
drug DRUGBANK Methionine
pathway REACTOME Translation
disease MESH RP11
drug DRUGBANK Flunarizine
drug DRUGBANK Tropicamide
drug DRUGBANK Calcium
disease MESH sepsis
disease MESH acute lung injury
pathway KEGG Tight junction
pathway REACTOME Glycolysis
disease MESH hyperacusis
drug DRUGBANK Trihexyphenidyl
drug DRUGBANK Profenamine
pathway REACTOME Mitophagy
disease MESH STING
disease MESH familial Mediterranean fever
disease MESH hyperimmunoglobulinemia
disease MESH coronavirus infection
disease MESH syndrome
pathway REACTOME Infectious disease
disease MESH Superinfection
disease MESH co infection
disease MESH idiopathic pulmonary fibrosis
disease MESH Schizophrenia
drug DRUGBANK (S)-Des-Me-Ampa
disease MESH obesity
disease MESH Ischemia Reperfusion Injury
drug DRUGBANK Carboxyamidotriazole
pathway REACTOME Sensory Perception
disease MESH autism spectrum disorders
disease MESH autism
disease MESH allergy
disease MESH LPS
disease MESH respiratory distress syndrome
pathway REACTOME Apoptosis
disease MESH Pulmonary Fibrosis
disease MESH acute kidney injury
disease MESH AML
disease MESH Park
disease MESH HIDS
disease MESH tumor
pathway REACTOME S Phase
pathway KEGG Viral replication
disease MESH Endotoxemia
pathway KEGG Efferocytosis
disease MESH Lung Injury

Original Article

(Visited 35 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *